Key result
Paclitaxel-coated balloon therapy did not increase delta troponin compared with paclitaxel-eluting stents or balloon angioplasty.
Why the study?
Does paclitaxel-coated balloon therapy increase high-sensitivity troponin compared to paclitaxel-eluting stents or plain balloon angioplasty in patients with limus-eluting stent restenosis?
RCT (n=343)
randomized
Does paclitaxel-coated balloon therapy increase high-sensitivity troponin compared to paclitaxel-eluting stents or plain balloon angioplasty in patients with limus-eluting stent restenosis?
In patients with drug-eluting stent restenosis, paclitaxel-coated balloons do not increase subclinical myocardial necrosis compared to paclitaxel-eluting stents or plain balloon angioplasty.
Answers are grounded in this paper and cite their sources.
Indicates no excess myocardial injury with PCB in DES restenosis; confirms safety equivalence to stents or angioplasty.
AIMS: The success of drug-coated balloon therapy might be compromised by intraprocedural particulate embolisation of matrix coating, which may cause downstream microvascular obstruction. We aimed to investigate whether drug-coated balloon therapy was associated with an increase in markers of myocardial necrosis compared with drug-eluting stents or plain balloon angioplasty. METHODS AND RESULTS: In the ISAR-DESIRE-3 trial, patients with limus-eluting stent restenosis were randomised to treatment with a paclitaxel-coated balloon (PCB), paclitaxel-eluting stent (PES) or balloon angioplasty. We included enrolled patients who had pre- and post-intervention high-sensitivity troponin (hs-TnT) levels available. The delta (peak post-procedure minus baseline) troponin was compared between treatment arms. The association between delta troponin tertiles and three-year mortality was also evaluated. Three hundred and forty-three (343) patients were included, comprising patients treated with PCB (n=115), PES (n=112) and balloon angioplasty (n=116). Groups were well matched in terms of baseline characteristics. There was no difference in delta troponin in patients treated with PCB, PES and balloon angioplasty (36±65, 70±183, and 51±124 ng/L, respectively, p=0.16). Three-year mortality was 7.7%, 8.8% and 14.3% for the 1st, 2nd and 3rd tertiles of delta troponin, respectively, p=0.23. CONCLUSIONS: In patients with drug-eluting stent restenosis, there was no difference in subclinical myocardial necrosis among patients treated with PCB, PES, and balloon angioplasty.
No takes yet. Share an insight, caveat, or question.
Colleran et al. (2017) conducted an RCT in limus-eluting stent restenosis (n=343). Paclitaxel-coated balloon (PCB) vs. Paclitaxel-eluting stent (PES) or balloon angioplasty was evaluated on delta (peak post-procedure minus baseline) troponin (p=0.16). Paclitaxel-coated balloon therapy did not increase delta troponin compared with paclitaxel-eluting stents or balloon angioplasty.
Synapse has enriched 10 related papers. Consider them for comparative context: